Senti Biosciences Ownership
| SNTI Stock | USD 4.36 0.34 8.46% |
Senti |
Senti Stock Ownership Analysis
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.32. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Senti Biosciences recorded a loss per share of 15.59. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of July 2024. Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Senti Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. To find out more about Senti Biosciences contact the company at 650 239 2030 or learn more at https://www.sentibio.com.Besides selling stocks to institutional investors, Senti Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Senti Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Senti Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Senti Biosciences Quarterly Liabilities And Stockholders Equity |
|
Senti Biosciences Insider Trades History
About 21.0% of Senti Biosciences are currently held by insiders. Unlike Senti Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Senti Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Senti Biosciences' insider trades
Senti Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Senti Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Senti Biosciences backward and forwards among themselves. Senti Biosciences' institutional investor refers to the entity that pools money to purchase Senti Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nea Management Company, Llc | 2024-09-30 | 442.6 K | Ark Investment Management Llc | 2024-12-31 | 28.0 | Vanguard Group Inc | 2024-09-30 | 97.5 K | Geode Capital Management, Llc | 2024-09-30 | 27.3 K | Ubs Group Ag | 2024-09-30 | 10.5 K | Blackrock Inc | 2024-09-30 | 4 K | Tower Research Capital Llc | 2024-09-30 | 2.4 K | Harbour Investments, Inc. | 2024-09-30 | 1.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 566 | Barclays Plc | 2024-09-30 | 500 | Bank Of America Corp | 2024-09-30 | 351 |
Senti Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Senti Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Senti Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Senti Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Senti Biosciences Outstanding Bonds
Senti Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Senti Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Senti bonds can be classified according to their maturity, which is the date when Senti Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| SENMED 2927 01 NOV 51 Corp BondUS81728XAA63 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ST 5875 01 SEP 30 Corp BondUS81725WAL72 | View | |
| US81725WAK99 Corp BondUS81725WAK99 | View | |
| SENIOR HSG PPTYS Corp BondUS81721MAM10 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Senti Biosciences Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 6th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 27th of January 2025 Other Reports | ViewVerify | |
| 15th of January 2025 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Senti Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.59) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Senti Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.